Egalet abuse-deterrent data show Oxaydo resists syringeability

US specialty pharma firm Egalet (Nasdaq: EGLT) today announced Category 1 abuse-deterrent data presented at PAINWeek 2016 demonstrate that Oxaydo (oxycodone HCl, USP) tablets CII resist syringeability which could potentially deter abuse through the intravenous route.

The data from a series of Category 1 studies of syringeability which assess abuse deterrence via the intravenous route of administration showed that Oxaydo forms a highly viscous gel that resisted preparation for injection and attempts to isolate oxycodone after manipulation. These results suggest that Oxaydo presents significant barriers to abuse via the intravenous route of administration. The data also demonstrated that the extraction of oxycodone from Oxaydo was significantly more difficult than from the comparator - a marketed generic immediate-release oxycodone.

"The Category 1 abuse-deterrent data for Oxaydo suggest that it may be difficult to abuse via the intravenous route," said Jeffrey Dayno, chief medical at Egalet. "Because the IV route of abuse poses the greatest safety risk, this is important additional data for Oxaydo which is the only marketed immediate-release opioid designed to discourage abuse via the intranasal route," he added.